CatalystAlert

Search CatalystAlert

Search for companies, drugs, and catalysts

Search CatalystAlert

Search for companies, drugs, and catalysts

Back to BGNE

Zanubrutinib Oral Product

Phase 2
BeiGene, Ltd. (BGNE)

Phase 2

Development Phase

1

Upcoming Catalysts

0

Historical Events

0

Regulatory Approvals

Upcoming Catalysts
What are catalysts?
Dec '26
BGNEPhase 2

Zanubrutinib Oral Product Phase 2 Est. Readout

Zanubrutinib Oral Product
Dec 2026~
CT.gov
00%
Competitive Landscape

0 competitors in Monoclonal Gammopathy of Uncertain Significance

View Full Landscape
Drug Information

Target Indication

Monoclonal Gammopathy of Uncertain Significance

Clinical Trial

NCT05939037

Last updated: 8/20/2026

Patent & Exclusivity

No patent data available. Pre-approval drugs may not have Orange Book listings.

Drug Science
Mechanism of action & safety profile
Get Catalyst Alerts
Receive weekly digests of upcoming catalysts

Weekly digest every Monday. Unsubscribe anytime.